Higher-Affinity Agonists of 5-HT1AR Discovered through Tuning the Binding-Site Flexibility

Discovery of high-affinity and high-selectivity agonists of 5-HT1AR has become very attractive due to their potential therapeutic effects on multiple 5-HT1AR-related psychological and neurological problems. On the basis of our previously designed lead compound FW01 (Ki = 51.9 nM, denoted as 9a in the present study), we performed large-scale molecular dynamics simulations and molecular docking operations on 5-HT1AR-9a binding. We found the flip-packing events for the headgroup of 9a, and we also found that its tail group could bind flexibly at the agonist-binding site of 5-HT1AR. By finely tuning the flip-packing phenomenon of the 9a headgroup and tuning the binding flexibility of 9a tail group, we virtually designed a series of new 9a derivatives through molecular docking operations and first-principles calculations and predicted that these newly designed 9a derivatives should be higher-affinity agonists of 5-HT1AR. The computational predictions on the new 9a derivatives have been confirmed by our wet-experimental studies as chemical synthesis, binding affinity assays, and agonistic-function assays. The consistency between our computational design and wet-experimental measurements has led to our discovery of higher-affinity agonists of 5-HT1AR, with ∼50-fold increase in receptor-binding affinity and ∼25-fold improvements in agonistic function. In addition, our newly designed 5-HT1AR agonists showed very high selectivity of 5-HT1AR over subtype 5-HT2AR and also over three subtypes of dopamine receptors (D1, D2, and D3).

[1]  P. Albert,et al.  5-HT1A Receptors, Gene Repression, and Depression: Guilt by Association , 2004, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[2]  P. Celada,et al.  Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research , 2013, CNS Drugs.

[3]  S. Dilly,et al.  Molecular modeling study of 4-phenylpiperazine and 4-phenyl-1,2,3,6-tetrahydropyridine derivatives: a new step towards the design of high-affinity 5-HT1A ligands. , 2010, Bioorganic & medicinal chemistry letters.

[4]  Peng Lian,et al.  Simulation Study of Coupling and Uncoupling Mechanisms of Cytochrome P 450 cam , 2013 .

[5]  K. Mine,et al.  Chronic treatment with tandospirone, a serotonin 1A receptor partial agonist, inhibits psychosocial stress-induced changes in hippocampal neurogenesis and behavior. , 2015, Journal of affective disorders.

[6]  Joseph P. Huston,et al.  Serotonin and psychostimulant addiction: Focus on 5-HT1A-receptors , 2007, Progress in Neurobiology.

[7]  Silvia Franchini,et al.  Discovery of a new series of 5-HT1A receptor agonists. , 2010, Bioorganic & medicinal chemistry letters.

[8]  Carsten Kutzner,et al.  GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.

[9]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[10]  Jeremy C. Smith,et al.  Catalytic mechanism and origin of high activity of cellulase TmCel12A at high temperature: a quantum mechanical/molecular mechanical study , 2014, Cellulose.

[11]  Kuo-Chen Chou,et al.  An Allosteric Mechanism Inferred from Molecular Dynamics Simulations on Phospholamban Pentamer in Lipid Membranes , 2011, PloS one.

[12]  Xuechu Zhen,et al.  (6aR)-11-Amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease , 2014, Pharmacology Biochemistry and Behavior.

[13]  C. Macedo,et al.  Involvement of median raphe nucleus 5-HT1A receptors in the regulation of generalized anxiety-related defensive behaviours in rats , 2008, Neuroscience Letters.

[14]  J. Łuszczki,et al.  Synthesis and biological investigation of potential atypical antipsychotics with a tropane core. Part 1. , 2011, European journal of medicinal chemistry.

[15]  H. Watts,et al.  Breakthrough Seizures after Starting Vilazodone for Depression , 2015, Pharmacotherapy.

[16]  M. Parrinello,et al.  Polymorphic transitions in single crystals: A new molecular dynamics method , 1981 .

[17]  J. Brotchie,et al.  Serotonin and Parkinson's disease: On movement, mood, and madness , 2009, Movement disorders : official journal of the Movement Disorder Society.

[18]  Bo Gao,et al.  Molecular Modeling of the 3D Structure of 5-HT1AR: Discovery of Novel 5-HT1AR Agonists via Dynamic Pharmacophore-Based Virtual Screening , 2013, J. Chem. Inf. Model..

[19]  Hoover,et al.  Canonical dynamics: Equilibrium phase-space distributions. , 1985, Physical review. A, General physics.

[20]  Adriano D Andricopulo,et al.  Pharmacophore-based 3D QSAR studies on a series of high affinity 5-HT1A receptor ligands. , 2010, European journal of medicinal chemistry.

[21]  S. Nosé A molecular dynamics method for simulations in the canonical ensemble , 1984 .

[22]  Yuxiang Bu,et al.  Tethered-hopping model for protein-DNA binding and unbinding based on Sox2-Oct1-Hoxb1 ternary complex simulations. , 2010, Biophysical journal.

[23]  Shanglin Zhou,et al.  Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile. , 2011, Journal of medicinal chemistry.

[24]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[25]  O. Berger,et al.  Molecular dynamics simulations of a fluid bilayer of dipalmitoylphosphatidylcholine at full hydration, constant pressure, and constant temperature. , 1997, Biophysical journal.

[26]  Hee-Jung Choi,et al.  Structural features of β2 adrenergic receptor: crystal structures and beyond. , 2015, Molecules and cells.

[27]  Quan Yuan,et al.  A Sleep-Promoting Role for the Drosophila Serotonin Receptor 1A , 2006, Current Biology.

[28]  Christian Kandt,et al.  Setting up and running molecular dynamics simulations of membrane proteins. , 2007, Methods.

[29]  A. Bojarski,et al.  Synthesis and biological evaluation of novel pyrrolidine-2,5-dione derivatives as potential antidepressant agents. Part 1. , 2013, European journal of medicinal chemistry.

[30]  Xuechu Zhen,et al.  Synthesis of dihydrofuroaporphine derivatives: identification of a potent and selective serotonin 5-HT 1A receptor agonist. , 2010, Journal of medicinal chemistry.

[31]  A. W. Schüttelkopf,et al.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.

[32]  Xuechu Zhen,et al.  Evaluation of the antipsychotic effect of bi-acetylated l-stepholidine (l-SPD-A), a novel dopamine and serotonin receptor dual ligand , 2009, Schizophrenia Research.

[33]  J. Ramos,et al.  New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo. , 2013, Journal of medicinal chemistry.

[34]  N. Veldman,et al.  5-HT1A-versus D2-receptor selectivity of flesinoxan and analogous N4-substituted N1-arylpiperazines. , 1997, Journal of medicinal chemistry.

[35]  M. Laruelle,et al.  In vitro assessment of the agonist properties of the novel 5-HT1A receptor ligand, CUMI-101 (MMP), in rat brain tissue. , 2011, Nuclear medicine and biology.

[36]  M F Sanner,et al.  Python: a programming language for software integration and development. , 1999, Journal of molecular graphics & modelling.

[37]  P. Pauwels,et al.  Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia , 2002, Neuropharmacology.

[38]  A. Andrews,et al.  Rethinking 5-HT1A receptors: emerging modes of inhibitory feedback of relevance to emotion-related behavior. , 2013, ACS chemical neuroscience.

[39]  S. Nosé,et al.  Constant pressure molecular dynamics for molecular systems , 1983 .

[40]  R. Stevens,et al.  Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.

[41]  Hualiang Jiang,et al.  Agonist-bound structure of the human P2Y12 receptor , 2014, Nature.

[42]  A. Leslie,et al.  Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation , 2011, Nature.

[43]  H. Berendsen,et al.  Interaction Models for Water in Relation to Protein Hydration , 1981 .

[44]  M. Thase,et al.  A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIXED-DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER , 2015, Depression and anxiety.

[45]  E. Lacivita,et al.  The therapeutic potential of 5-HT1A receptors: a patent review , 2012, Expert opinion on therapeutic patents.

[46]  I. Seif,et al.  Reduced density of functional 5‐HT1A receptors in the brain, medulla and spinal cord of monoamine oxidase‐A knockout mouse neonates , 2006, The Journal of comparative neurology.

[47]  Xuechu Zhen,et al.  l-Stepholidine reduced l-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease , 2010, Neurobiology of Aging.